Published in Antimicrob Agents Chemother on April 02, 2012
The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med (2013) 1.64
A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar J (2012) 0.97
Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial. PLoS Med (2014) 0.90
Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrob Agents Chemother (2015) 0.87
Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother (2014) 0.87
Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. Antimicrob Agents Chemother (2015) 0.85
Auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination. Malar J (2014) 0.83
Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women. Br J Clin Pharmacol (2016) 0.81
Validation and Application of a Dried Blood Spot Assay for Biofilm-Active Antibiotics Commonly Used for Treatment of Prosthetic Implant Infections. Antimicrob Agents Chemother (2016) 0.79
Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLoS Med (2017) 0.76
Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children. Antimicrob Agents Chemother (2017) 0.75
Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing. Antimicrob Agents Chemother (2014) 0.75
The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation. PLoS One (2016) 0.75
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg (2000) 22.12
Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem (2003) 6.77
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J (2011) 4.60
Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol (2004) 3.48
Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis (2002) 3.40
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis (2007) 3.27
How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health (2007) 3.13
The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. Am J Trop Med Hyg (1986) 3.04
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn (2007) 3.00
Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet (2009) 2.92
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov (2007) 2.71
Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.29
Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Am J Trop Med Hyg (1997) 2.27
Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother (2008) 2.23
Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther (2006) 2.18
Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One (2009) 2.05
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother (2007) 2.02
Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother (2005) 2.00
Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg (1996) 1.90
Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother (2005) 1.79
Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos (1998) 1.67
Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother (2007) 1.64
Selective high-performance liquid chromatographic determination of artesunate and alpha- and beta-dihydroartemisinin in patients with falciparum malaria. J Chromatogr B Biomed Appl (1996) 1.54
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother (2009) 1.52
Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am J Trop Med Hyg (2008) 1.47
Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol (2002) 1.38
Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. Br J Clin Pharmacol (1996) 1.35
Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur J Clin Pharmacol (2006) 1.31
A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol (2005) 1.28
The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop (2008) 1.19
Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob Agents Chemother (2002) 1.18
Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br J Clin Pharmacol (1998) 1.14
Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses. Biopharm Drug Dispos (1998) 1.13
A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob Agents Chemother (2011) 1.09
Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. Br J Clin Pharmacol (2005) 1.09
Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. J Clin Pharmacol (2008) 1.09
Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin. Eur J Clin Pharmacol (2000) 1.09
Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther (1998) 1.08
The pharmacokinetics of a single dose of artemisinin in healthy Vietnamese subjects. Am J Trop Med Hyg (1994) 1.06
Dose ranging studies of new artemisinin-piperaquine fixed combinations compared to standard regimens of artemisisnin combination therapies for acute uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health (2007) 1.06
Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects. Antimicrob Agents Chemother (2008) 1.02
A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. Chin J Integr Med (2009) 0.94
Pharmacokinetics of piperaquine after single and multiple oral administrations in healthy volunteers. Yakugaku Zasshi (2007) 0.91
Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication. PLoS Negl Trop Dis (2010) 0.87
Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis (2008) 9.87
A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med (2008) 4.77
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol (2004) 3.48
Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis (2002) 3.40
Reported reasons for not using a mosquito net when one is available: a review of the published literature. Malar J (2011) 3.16
Clinical and laboratory features of human Plasmodium knowlesi infection. Clin Infect Dis (2009) 2.92
Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clin Infect Dis (2008) 2.80
Piperaquine: a resurgent antimalarial drug. Drugs (2005) 2.80
The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg (2007) 2.72
Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev (2007) 2.50
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 2.22
Comparison of three antigen detection methods for diagnosis and therapeutic monitoring of malaria: a field study from southern Vietnam. Trop Med Int Health (2002) 2.22
Evaluation of serological diagnostic tests for typhoid fever in Papua New Guinea using a composite reference standard. Clin Vaccine Immunol (2012) 2.21
Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol (2009) 2.20
Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care (2004) 2.09
Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care (2006) 2.09
Overview of methods in economic analyses of behavioral interventions to promote oral health. J Public Health Dent (2011) 2.05
Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun (2003) 2.02
Molecular evidence for the localization of Plasmodium falciparum immature gametocytes in bone marrow. Blood (2013) 2.01
Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother (2005) 2.00
Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust (2005) 1.98
Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis (2009) 1.95
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
Rise in malaria incidence rates in South Africa: a small-area spatial analysis of variation in time trends. Am J Epidemiol (2002) 1.88
Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One (2010) 1.87
Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol (2004) 1.84
Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis (2006) 1.82
The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. AIDS (2008) 1.81
Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis (2010) 1.79
Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos (2002) 1.70
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol (2013) 1.68
Strategies for detection of Plasmodium species gametocytes. PLoS One (2013) 1.67
A sub-microscopic gametocyte reservoir can sustain malaria transmission. PLoS One (2011) 1.67
Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Med J Aust (2009) 1.67
Comparison of Plasmodium falciparum allelic frequency distribution in different endemic settings by high-resolution genotyping. Malar J (2009) 1.67
Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother (2007) 1.64
Clinical immunity to malaria. Curr Mol Med (2006) 1.63
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A (2008) 1.63
Comparison of diagnostic methods for the detection and quantification of the four sympatric Plasmodium species in field samples from Papua New Guinea. Malar J (2010) 1.60
Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS One (2011) 1.55
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br J Clin Pharmacol (2002) 1.48
Insecticidal bed nets and filariasis transmission in Papua New Guinea. N Engl J Med (2013) 1.48
Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis (2011) 1.47
Multilocus haplotypes reveal variable levels of diversity and population structure of Plasmodium falciparum in Papua New Guinea, a region of intense perennial transmission. Malar J (2010) 1.47
Clonal origins of Vibrio cholerae O1 El Tor strains, Papua New Guinea, 2009-2011. Emerg Infect Dis (2011) 1.46
Ownership and usage of mosquito nets after four years of large-scale free distribution in Papua New Guinea. Malar J (2012) 1.45
Reduced Plasmodium vivax erythrocyte infection in PNG Duffy-negative heterozygotes. PLoS One (2007) 1.45
Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study. J Vasc Surg (2009) 1.41
Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care (2005) 1.41
Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care (2006) 1.40
The current status and potential role of laboratory testing to prevent transfusion-transmitted malaria. Transfus Med Rev (2005) 1.36
Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. Nat Genet (2012) 1.34
A comparison of the sensitivities of detection of Plasmodium falciparum gametocytes by magnetic fractionation, thick blood film microscopy, and RT-PCR. Malar J (2009) 1.32
Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother (2011) 1.32
Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.30
Outbreak of chikungunya virus infection, Vanimo, Papua New Guinea. Emerg Infect Dis (2013) 1.29
Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Malar J (2010) 1.29
Enhanced detection of gametocytes by magnetic deposition microscopy predicts higher potential for Plasmodium falciparum transmission. Malar J (2008) 1.28
Diabetes education and knowledge in patients with type 2 diabetes from the community: the Fremantle Diabetes Study. J Diabetes Complications (2003) 1.27
Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria. J Immunol (2010) 1.26
B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial. Ann Neurol (2010) 1.25
Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob Agents Chemother (2011) 1.24
The stability and complexity of antibody responses to the major surface antigen of Plasmodium falciparum are associated with age in a malaria endemic area. Mol Cell Proteomics (2011) 1.24
How much remains undetected? Probability of molecular detection of human Plasmodia in the field. PLoS One (2011) 1.23
Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. PLoS One (2012) 1.23